Tim Casey

Treatment with Canagliflozin for 52 Weeks

10/23/2013

San Diego—After 52 weeks of treatment, patients with type 2 diabetes who received 100 mg or 300 mg of canagliflozin had reductions in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure, according to...

San Diego—After 52 weeks of...

10/23/2013

First Report Managed Care

Evolving Treatment Strategies for Myeloma

06/26/2013

Tim Casey ;

Orlando—Since 2000, the number of treatments for myeloma has expanded with the introduction of proteasome inhibitors and other immunomodulatory agents. Still, the disease is complex, and there are multiple options available for the treatment...

Orlando—Since 2000, the number...

06/26/2013

First Report Managed Care

Preferred and Limited Pharmacy Networks Could Save Billions

02/14/2013

Tim Casey ;

In recent years, high-profile disagreements between pharmacies and pharmacy benefit managers (PBMs) have caused many companies to consider narrow pharmacy networks to generate savings. Rather than the typical process in which plans create a...

In recent years, high-profile...

02/14/2013

First Report Managed Care

Treatment Options for Neuropathic Pain

10/22/2012

Tim Casey ;

Phoenix—When Mark Wallace, MD, began his medical career in 1995, the FDA had approved only a single drug for neuropathic pain. Now his choices are much broader, although the approval of several medications in recent years has made it...

Phoenix—When Mark Wallace, MD,...

10/22/2012

First Report Managed Care

FDA, Health Canada, and EMA Regulators Seek Collaboration

07/23/2012

Tim Casey ;

Like her colleagues throughout the world, Margaret Hamburg, MD, has been dealing with issues that she could have never foreseen when she became the FDA’s commissioner in May 2009. Science continues to advance rapidly, making it difficult to...

Like her colleagues throughout...

07/23/2012

First Report Managed Care

Quality of Life Care in Chronic Lymphocytic Leukemia Patients

01/25/2012

Tim Casey ;

San Diego—A prospective, longitudinal, observational study found that the health-related quality of life (HRQOL) in patients with chronic lymphocytic leukemia (CLL) did not differ based on age. In addition, the most common type of first-line...

San Diego—A prospective,...

01/25/2012

First Report Managed Care

Oral Antidiabetics for Type 2 Diabetes and Chronic Kidney Disease

09/19/2011

Tim Casey ;

San Diego—An examination of electronic health record data from an integrated health system found that patients with type 2 diabetes and chronic kidney disease who had an oral antidiabetic drug regimen concordant with National Kidney...

San Diego—An examination of...

09/19/2011

First Report Managed Care

Feature

Aspirin versus Placebo Does Not Result in Significant Reduction in Vascular Events

06/28/2010

Tim Casey ;

In an intention-to-treat, double-blind, randomized controlled trial, researchers found that the administration of aspirin compared with placebo did not result in a significant reduction in vascular events among participants without clinical...

In an intention-to-treat,...

06/28/2010

First Report Managed Care

Feature

Medicaid Beneficiaries and Serious Mental Illness

04/18/2011

Tim Casey ;

Arlington, Virginia—Medicaid patients with serious mental illness are less inclined to adhere to their medications, visit providers, and undergo preventive services. Many also have chronic conditions and risk factors such as smoking, poor...

Arlington, Virginia—Medicaid...

04/18/2011

First Report Managed Care

Conference Insider

Costs and Hospitalizations Associated with Hemophilia

12/18/2013

Tim Casey ;

Patients with hemophilia who develop inhibitors had a lower frequency of hospitalizations and had costs 3 times lower than people who did not develop inhibitors.

Patients with hemophilia who...

12/18/2013

First Report Managed Care